MEL-SELF试验:筛查与随机入组参与者的基线特征
MEL-SELF随机临床试验(RCT)评估患者主导监测作为随访替代模式。本二次分析描述筛查和随机入组参与者的基线特征:1226例筛查者中504例随机分组,患者主导监测组251例、临床医生主导监测组253例;参与者皮肤自查(SSE)实践不足,46%报告临床显著水平的癌症复发恐惧(FCR)。
要点
- 筛查人群中仅504/1226例随机入组,参与者多为50岁以上、早期黑色素瘤(原位或IA期)。
- SSE实践差异大:20%近12个月无SSE,32%每周或每月SSE。
- 46%报告临床显著FCR,与女性、年轻、抑郁焦虑压力评分高相关。
核心结论
- MEL-SELF试验基线数据显示早期黑色素瘤随访人群SSE实践不理想且FCR水平较高。
研究设计与样本
- 基于MEL-SELF RCT招募过程的基线数据分析,时间为2021年12月至2024年6月,数据来自澳大利亚皮肤科和全科医生主导的皮肤癌诊所。
- 纳入既往接受早期黑色素瘤(AJCC 0-II期)治疗、定期就诊、有SSE伙伴和智能手机的成人;共筛查1226例潜在合格者,随机504例(患者主导监测251例,临床医生主导监测253例)。
主要发现
- 随机入组504例中女性295例(59%)、男性209例(41%),平均(SD)年龄56.0(11.6)岁,最高亚期为原位245例(49%)或IA期217例(43%)。
- SSE实践从近12个月无SSE(103例,20%)到每周或每月SSE(160例,32%)不等。
- 232例(46%)报告临床显著FCR,与女性、年轻年龄及较高抑郁、焦虑、压力评分相关。
- FCR与感知一生黑色素瘤风险较高相关,但与实际计算的新原发黑色素瘤风险无关(OR,1.00;95%CI,0.99-1.01)。
- 试验人群与完成基线问卷但未随机化的潜在合格患者(n=225)特征相似。
临床怎么用
- 在早期黑色素瘤随访中应评估患者SSE实践和FCR,针对女性、年轻及心理困扰者加强支持。
局限性
- 本分析为基线描述性二次分析,不能评估患者主导监测的比较效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The MEL-SELF randomized clinical trial (RCT) evaluated patient-led surveillance as an alternative model of follow-up. The baseline characteristics of participants provide insights into current unmet clinical needs of this population. OBJECTIVE: To describe the baseline characteristics of people screened for and randomized to the MEL-SELF RCT, and those potentially eligible but not randomized. DESIGN, SETTING, AND PARTICIPANTS: Baseline data from the RCT's recruitment processes, from December 2021 to June 2024, were analyzed. Data were collected from dermatologist- and general practitioner-led skin cancer clinics in Australia, and included adults previously treated for early-stage melanoma (by American Joint Committee on Cancer Staging Manual [AJCC, 0-II]) attending routinely scheduled clinics, with a skin self-examination (SSE) partner, and a smartphone. Analysis took place between August 2025 and December 2025. INTERVENTIONS: Participants were invited to participate in the MEL-SELF trial with randomization (1:1) to patient-led surveillance (usual care plus reminders to perform SSE, mobile dermatoscope, teledermatologist assessment, fast-tracked unscheduled clinic visits) or clinician-led surveillance (usual care) for 12 months. MAIN OUTCOMES AND MEASURES: The main outcomes were enrollment; active run-in and allocation results, sociodemographic and clinical characteristics; SSE knowledge, attitudes, and practice (frequency and thoroughness); and psychological measures including fear of cancer recurrence (FCR) at baseline. RESULTS: Of 1226 patients screened and potentially eligible, 504 were randomized to patient-led (n = 251) or clinician-led (n = 253) surveillance. Overall, 295 were female individuals (59%) and 209 were male individuals (41%), most were aged 50 years and older (mean [SD] age, 56.0 [11.6] years) and had a highest substage of melanoma in situ (245 [49%]) or IA (217 [43%]). SSE practice varied substantially, ranging from no SSE in the previous 12 months (103 [20%]) to weekly or monthly SSE (160 [32%]). A high proportion (232 [46%]) reported clinically significant levels of FCR, which was associated with being female, younger age, and higher depression, anxiety, and stress scores. FCR was associated with a higher perceived lifetime risk of melanoma, but not with participants' actual calculated risk of a subsequent new primary melanoma (OR, 1.00; 95% CI, 0.99-1.01). Characteristics were similar between the trial population and potentially eligible patients who completed the baseline questionnaire but were not randomized (n = 225). CONCLUSIONS: This secondary analysis of baseline characteristics in the MEL-SELF trial indicates suboptimal SSE practice and clinically significant levels of FCR. Future reports will evaluate comparative effects of patient-led surveillance on health, psychological and health resource use outcomes. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12621000176864.
引用
- Medcalf E, Ackermann DM, Williams JTW, et al. Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. JAMA Dermatol. 2026. PMID: 41811339. doi:10.1001/jamadermatol.2026.0083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。